Leadership

 

Leadership

All of us at Heat have been personally touched by cancer, or have witnessed firsthand the devastating effects of the disease and its current treatment methods on loved ones. Our team is fully dedicated to helping eradicate cancer through the development of safer, more effective therapies that enhance the immune system rather than destroying it.

Jeffrey Wolf
Founder and CEO

Jeffrey Wolf is founder and CEO of Heat Biologics, and co-founder of Pelican Therapeutics. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon breakthrough research.

Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground-up, and has played an active role in supporting the growth of his companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases; and GenerationOne (founder and CEO), one of the first mobile-based health companies focused on disease management.

Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.

Jeff Hutchins, PhD
Chief Scientific and Operating Officer

As Chief Scientific and Operating Officer, Jeff Hutchins oversees the research and development efforts for Heat Biologics, as well as for the company’s subsidiary, Pelican Therapeutics. He brings more than 24 years of research and clinical development experience from both pharmaceutical- and biotechnology-focused companies. Most recently, Dr. Hutchins served as Vice President of Pre-clinical Research for Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins was responsible for building out the research program for Peregrine’s lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine.

Prior to joining Peregrine in 2012, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb. From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College.

Dr. Hutchins earned his Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center, followed by postdoctoral training in the University of Southern California’s Department of Microbiology at the Norris Cancer Center. Dr. Hutchins’ publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology. He received his B.S. in Biology from Oral Roberts University.

George Peoples, M.D., FACS
Chief Medical Advisor

U.S. Army, COL (ret) George E. Peoples, MD, FACS, serves as CMO for both Heat Biologics and its subsidiary, Pelican Therapeutics. Dr. Peoples is currently professor of surgery at Uniformed Services University of the Health Sciences, as well as adjunct professor of surgical oncology at MD Anderson Cancer Center (MDACC). He is also the founder and director of Cancer Insight, LLC, a clinical research and development organization dedicated to the discovering, development and testing for emerging biotechnologies specializing in cancer immunotherapy.

Dr. Peoples recently retired from 30 years of active duty as a surgeon and as a research scientist in the military. He is the past chair of the cancer program at the San Antonio Military Medical Center, and the past deputy director of the United States Military Cancer Institute. Prior to that, he served as chief of surgical oncology at Walter Reed Amy Medical Center (WRAMC), as well as SAMMC. He is a graduate of the United States Military Academy, West Point and Johns Hopkins School of Medicine.

Dr. Peoples completed his surgical training at Harvard’s Brigham and Women’s Hospital, and during that time, also completed a post-doctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC. Dr. Peoples has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts and book chapters.

Ann A. Rosar, MBA
Vice President of Finance, Corporate Secretary

Ann Rosar joined our company as Controller January 2015 and was named Vice President of Finance April 2016. Ms. Rosar has over 20 years of experience in finance with publicly held companies and more than 15 years of experience regarding regulatory reporting requirements. Prior to joining Heat Biologics, Ms. Rosar served as Manager of Financial Reporting and Accounting for LipoScience, Inc. (acquired by LabCorp), a provider of specialized cardiovascular diagnostic tests, from 2013 to 2015. From 2007 until 2013 she served in various roles at DARA Biosciences, Inc. (now Midatech Pharma US), an oncology supportive care pharmaceutical company, including Vice President of Finance, Chief Accounting Officer and Controller. Earlier in her career, Ms. Rosar had also been responsible for Securities and Exchange Commission reporting, audits and budget analysis at Cicero, Inc. (formerly Level 8 Systems) a business integration software provider; as well as Senior Financial Analyst-Business Operations for Nextel Communications.

Ms. Rosar received an MBA in Finance with high honors from the University of Houston and received her undergraduate degrees from North Carolina State University.

Janice Marie McCourt, RPh, MBA
Executive Vice President, Business Development

Janice Marie McCourt, leads business development and partner alliances. She has 25 years of experience leading pharma and biotech companies globally; working across the R&D-to-commercial continuum in business development, commercial and clinical development. Ms. McCourt has raised over $3 billion in global licensing, acquisition, investment and partnerships. Previously, she led the strategic and tactical diversification of Agenus from a vaccines-focused company directly into the antibody checkpoint modulation space with the acquisition of 4-Antibody, thereby establishing the company as a leader in immuno-oncology.

Ms. McCourt has been on executive management teams, leading commercial strategy and business development at Edgemont Pharmaceuticals, Amakem Therapeutics and Praecis Pharmaceuticals (now GSK). She spent five years at Ingenix, the $1.5 billion consulting arm of UnitedHealth Group, leading both commercial and development projects with top-tier pharmaceutical and biotech companies. As the first commercial hire at TAP Pharmaceuticals, she was promoted numerous times in various management commercial roles. She has led many product launches for major brands in immuno-oncology, CNS, immunology, inflammation, women’s health, neurology, respiratory, ophthalmology, infectious disease, vaccines and pain therapeutic areas.

Ms. McCourt graduated from Massachusetts College of Pharmacy and Allied Health Sciences, where she completed her clinical rotation at Harvard Medical School on the internal medicine, gastroenterology, and cardiac units, and also has an MBA with high honors.

Lori McDermott, RN, BSN, MS, PMP
Vice President, Clinical Development

As Vice President of clinical development, Lori McDermott oversees the strategic and operational aspects of clinical drug development for Heat Biologics, as well as for the company’s subsidiary, Pelican Therapeutics.

Ms. McDermott brings more than 18 years of clinical operations and program management experience, spanning across large and small pharmaceutical companies, as well as contract research organizations. Prior to joining Heat Biologics, Ms. McDermott held positions of increasing responsibility at Astra-Zeneca, ICON, Bausch & Lomb, PPD and Peregrine Pharmaceuticals. Ms. McDermott’s responsibilities have included the execution of clinical trial programs, from Phase 1 to 4, with a recent focus on immunotherapy development in non-small cell lung cancer. Prior to her work in clinical research, Ms. McDermott practiced as a registered nurse and is currently licensed in Pennsylvania and Florida.

Ms. McDermott received an M.S. in clinical research organization and management from Drexel University College of Medicine, and her B.S. in Nursing from Neumann College. She is also certified as a PMP by the Project Management Institute.

Gary Vinson
Vice President, Chemistry and Manufacturing Controls (CMC)

As Vice President of Chemistry and Manufacturing Controls, Gary Vinson is responsible for all manufacturing and analytical development for Heat Biologics, as well as for the company’s subsidiary, Pelican Therapeutics.

He has more than 20 years of experience in the pharmaceutical, CRO/CMO and biotechnology industries, in technical, development and quality roles. Prior to joining Heat, he held roles as Vice President, Pharmaceutical Development at a specialty pharmaceutical company, BioDelivery Sciences, and at Aldagen, a clinical-stage regenerative medicine company developing adult cell therapies. His responsibilities have included leading manufacturing, analytical development and quality organizations, and he has significant experience developing CDMO outsourcing relationships from pre-IND through to registration. Mr. Vinson founded and was Managing Partner of The Perdoceo Group, LLC, a consulting firm providing CMC support to biotechnology and pharmaceutical clients. He began his career with Glaxo, Inc. and worked at Magellan Laboratories, where he was a principal in establishing the pharmaceutics group to provide contract development and manufacturing of clinical trial materials.

Mr. Vinson received his B.S. In Chemistry from North Carolina State University and holds CPGP (Certified GMP Professional) and RAC (Regulatory Affairs Certification) certifications.